Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.
The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.
Links to related guidelines are provided separately. (See "Society guideline links: Diabetes mellitus in adults" and "Society guideline links: Chronic kidney disease in adults".)
International
●American Diabetes Association (ADA) and Kidney Disease Improving Global Outcomes (KDIGO): Consensus report on diabetes management in chronic kidney disease (2022)
●KDIGO: Clinical practice guideline for diabetes management in chronic kidney disease (2022)
Canada
●Choosing Wisely Canada: Don't prescribe angiotensin converting enzyme (ACE) inhibitors in combination with angiotensin II receptor blockers (ARBs) for the treatment of hypertension, diabetic nephropathy and heart failure (2021)
●Choosing Wisely Canada: Don't prescribe nonsteroidal anti-inflammatory drugs (NSAIDs) in individuals with hypertension or heart failure or CKD of all causes, including diabetes (2021)
●Diabetes Canada: Clinical practice guidelines on chronic kidney disease in diabetes (2018)
United States
●American Diabetes Association (ADA): Standards of care in diabetes (2023)
•Comprehensive medical evaluation and assessment of comorbidities
•Cardiovascular disease and risk management
•Chronic kidney disease and risk management
●ADA and Kidney Disease: Improving Global Outcomes (KDIGO): Consensus report on diabetes management in chronic kidney disease (2022)
●Kidney Disease Outcomes Quality Initiative (KDOQI) and Academy of Nutrition and Dietetics (AND): Clinical practice guideline for nutrition in CKD, update (2020)
●ADA: Diabetic kidney disease – A report from an ADA consensus conference (2014)
Europe
●European Society of Cardiology (ESC): Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with EASD (2019)
United Kingdom
●Association of British Clinical Diabetologists (ABCD) and UK Kidney Association (UKKA): Consensus statement on finerenone in the management of diabetic kidney disease (2023)
●UKKA: Clinical practice guideline on sodium-glucose co-transporter-2 (SGLT-2) inhibition in adults with kidney disease (2023)
●National Institute for Health and Care Excellence (NICE): Guideline on type 1 diabetes in adults – Diagnosis and management (2015, updated 2022)
●ABCD and The Renal Association: Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease, update (2021)
•ABCD and The Renal Association: Managing hyperglycaemia in patients with diabetes and diabetic nephropathy-chronic kidney disease (2018)
●ABCD and The Renal Association: Clinical practice guidelines for management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease, update (2021)
●ABCD and The Renal Association: Clinical practice guidelines for management of lipids in adults with diabetic kidney disease, update (2021)
●NICE: Guideline on chronic kidney disease – Assessment and management (2021)
India
●Research Society for the Study of Diabetes in India (RSSDI): Clinical practice recommendations for the management of type 2 diabetes mellitus (2022)
●Endocrine Society of Bengal: Kidney disease in type 2 diabetes mellitus and benefits of sodium-glucose cotransporter 2 inhibitors – A consensus statement (2020)
●Consensus statement on insulin therapy in chronic kidney disease (2017)
●Management of anemia in patients with diabetic kidney disease – A consensus statement (2016)
Australia–New Zealand
●Choosing Wisely Australia: Do not intensively lower HbA1C<6.5% to <8.0% in patients with early (stage 1-3) chronic kidney disease as intense lowering increases the risk of hypoglycaemia and mortality, noting that the individual target depends on factors such as severity of CKD, macrovascular complications, comorbidities, life expectancy and others (2021)
Japan
●[In Japanese] Japanese Society of Nephrology (JSN): 2022 Recommendations on proper use of SGLT2 inhibitors in CKD treatment (published 2023)
